GI
BCRX icon

GAMMA Investing’s BioCryst Pharmaceuticals BCRX Stock Holding History

GAMMA Investing’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.7K Buy
1,290
+61
+5% +$574 ﹤0.01% 3288
2026
Q2 		$12.3K Buy
1,229
+11
+0.9% +$99 ﹤0.01% 3102
2026
Q1 		$11.6K Buy
1,218
+977
+405% +$7.59K ﹤0.01% 2998
2025
Q4 		$1.88K Sell
241
-104
-30% -$752 ﹤0.01% 3620
2025
Q3 		$2.62K Sell
345
-70
-17% -$583 ﹤0.01% 3379
2025
Q2 		$3.72K Sell
415
-374
-47% -$3.48K ﹤0.01% 3224
2025
Q1 		$5.92K Buy
789
+320
+68% +$2.58K ﹤0.01% 3015
2024
Q4 		$3.53K Buy
469
+124
+36% +$941 ﹤0.01% 3049
2024
Q3 		$2.62K Buy
345
+191
+124% +$1.45K ﹤0.01% 2981
2024
Q2 		$952 Buy
154
+46
+43% +$254 ﹤0.01% 3069
2024
Q1 		$549 Buy
108
+1
+0.9% +$6 ﹤0.01% 3091
2023
Q4 		$567 Buy
+107
New +$620 ﹤0.01% 2936

Other funds holding BCRX

WCM
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
RF
RHS Financial San Francisco, California $296M AUM 17.24% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing's BCRX Position: Q3 2026 in Review

GAMMA Investing increased its BioCryst Pharmaceuticals (BCRX) stake by 5% in Q3 2026, buying an estimated $574 and bringing the position to 1,290 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3288.

GAMMA Investing first reported a position in BCRX in Q4 2023 and has held it in 12 quarters since. The position peaked at $12.3K in Q2 2026. 11 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • GAMMA Investing held 1,290 shares of BioCryst Pharmaceuticals worth $10.7K as of Q3 2026.
  • GAMMA Investing bought 61 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $574.
  • BioCryst Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3288 holding.
  • GAMMA Investing first reported a position in BioCryst Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's BioCryst Pharmaceuticals position peaked at $12.3K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.